The size of the Global Chlamydia Infection Diagnostics and Therapeutics Market was around USD 2.4 billion in 2020. It is expected to grow at a CAGR of 6.06% to reach USD 3.2 billion by 2025.
Chlamydia is a sexually transmitted disease. The symptoms do not occur early on. It is usually prevalent in areas with poor sanitation. It is the most common STD worldwide. The number of victims has been increasing over the last decade.
MARKET DRIVERS:
Y-O-Y growth in the prevalence and incidence rate of chlamydia infection globally, Y-O-Y growth in the academic research activities, and increasing strategic partnerships between market players and leading research institutes are primarily accelerating the global chlamydia infection diagnostics and therapeutics market.
Additionally, increasing screening coverage and more holistic reporting, particularly in developed countries, higher spending in healthcare in both advanced and emerging economies, availability of sensitive diagnostic tests are other significant factors driving the global chlamydia infection diagnostics therapeutics market. According to the Centre for Disease Control and Prevention, the overall number of chlamydia infection cases confirmed to the CDC in the United States was 1,526,658 in 2015. In other parts of the world, numbers are still at an alarming pace. The rising need for fast and successful diagnostic tests and therapeutics to address this rapidly increasing patient pool is pushing the chlamydia infection diagnostics and therapeutics industry to new heights. Access to and affordability of hypersensitive diagnostic testing are also contributing to the market's growth.
MARKET RESTRAINTS:
The global demand for chlamydia infection diagnostics and therapeutics is hindered by lack of knowledge of chlamydia diagnostic tests in low and middle-income countries and the stigma associated with voluntary chlamydia screening; the negative societal effect can hamper market development. The most common group for chlamydia infection is those between the ages of 16 and 25, who fear social embarrassment, leading to untreated or undiagnosed chlamydia infections.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Covered |
By Product, End User, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
This research report on the global chlamydia infection diagnostics and therapeutics market has been segmented and sub-segmented based on the product, end-user, and region.
Chlamydia Infection Diagnostics and Therapeutics Market – By Product:
Based on product, the NAAT segment is accounted for the largest market share in 2016 and is predicted to grow robustly in the forecast period. It is closely tailed by DFT in terms of CAGR. This is because NAATs are more sensitive and diagnose better. Macrolides are expected to undergo high growth in the forecast period. It also captures the largest market share and is expected to stay at the top in the forecast period.
Chlamydia Infection Diagnostics and Therapeutics Market – By End User:
Chlamydia Infection Diagnostics and Therapeutics Market – By Region:
North America is the largest regional market, while the Asia Pacific is expected to be the fastest-growing market worldwide. The growth of the North American market is majorly driven by the well-established health-care sector, the chlamydia infection rates, and the provision of well-defined reimbursement policies from public and private health insurance companies. Due in part to proactive public and private sector awareness campaigns, better diagnosis and treatment rates have also resulted in North America capturing the predominant share of the global market.
Due to the emergence of several developing economies and a broad population base, Asia Pacific is another promising market. Generics are the most commonly marketed drugs in the country because the demand is price sensitive. The growth of the Asia Pacific market is expected to expand due to factors such as a wide pool of potential customers, the introduction of government policies aimed at expanding health care coverage, improving facilities, and increasing health care spending.
In Europe, the market is expected to reach the highest CAGR during the forecast period.
KEY MARKET PARTICIPANTS:
Some of the notable companies leading the global chlamydia infection diagnostics and therapeutics market profiled in this report are Bio-Rad Laboratories, Novartis AG, F Hoffmann-La Roche, Abbott Laboratories, Danaher. Other players in the market include bioMerieux, DiaSorin SpA, Siemens AG, Thermo Fisher Scientific, and Becton Dickinson and Company.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.1 Introduction
5.1.2 Diagnostics
5.1.2.1 Nucleic Acid Amplification Tests (NAATs)
5.1.2.2 Direct Fluorescent Tests
5.1.2.3 PCR
5.1.3 Therapeutics
5.1.3.1 Macrolides
5.1.3.2 Quinolones
5.1.3.3 Sulfonamides
5.1.3.4 Tetracycline
5.1.3.5 Aminopenicillins
5.1.4 Y-o-Y Growth Analysis, By Product Type
5.1.5 Market Attractiveness Analysis, By Product Type
5.1.6 Market Share Analysis, By Product Type
5.2 End User
5.2.1 Introduction
5.2.2 Diagnostics
5.2.2.1 Hospitals
5.2.2.2 Specialty Clinics
5.2.2.3 Diagnostic Centers
5.2.3 Therapeutics
5.2.3.1 Hospital Pharmacies
5.2.3.2 Drugstores
5.2.3.3 Retail Pharmacies
5.2.3.4 Online Pharmacies
5.2.4 Y-o-Y Growth Analysis, By End User
5.2.5 Market Attractiveness Analysis, By End User
5.2.6 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product Type
6.1.3.3 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product Type
6.1.4.3 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product Type
6.1.5.3 By End User
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Bio Rad laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novartis AG
8.3 F Hoffmann-La Roche
8.4 Abbott Laboratories
8.5 Danaher
8.6 bioMerieux
8.7 DiaSorin SpA
8.8 Siemens AG
8.9 Thermo Fisher Scientific
8.10 Becton Dickinson and Company
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
